Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

Fig. 3

Kaplan–Meier survival plots of progression-free survival (PFS) in different patient groups in this cohort. a Patients with baseline mTBI level below 6.81% had longer PFS compared to those above (P = 0.0115). b Patients with identification of new mutations during treatment had a significant shorter PFS than the patients without identification of new mutations (P = 0.0003). c Patients with fold reduction in mTBI above 0.8-fold had longer PFS compared to those below (P = 0.0115)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us